NASDAQ$KIDS
OrthoPediatrics Corp · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
OrthoPediatrics experienced a revenue decline due to the COVID-19 pandemic but showed monthly improvement and advanced key initiatives.
OrthoPediatrics Corp. reported a 25.3% decrease in total revenue for Q2 2020, totaling $13.6 million, compared to $18.2 million in Q2 2019. The decline was primarily due to the impact of the COVID-19 pandemic. Despite the decrease, the company saw significant monthly improvement throughout the quarter and continued to execute key initiatives, including the acquisition and launch of the ApiFix system.
- Total revenue for Q2 2020 was $13.6 million, a 25.3% decrease compared to Q2 2019.
- U.S. revenue decreased by 12.3% compared to the same period last year.
- The company commenced the initial U.S. launch of the ApiFix system following its acquisition.
- The domestic sales organization expanded to 164 consultants, a 7.9% increase from Q2 2019.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$13.6M
Revenue by segment
OrthoPediatrics · $13.6M total across 3 segments · Q2 2020
- Trauma and Deformity$9.22M-22.4%67.8%
- Scoliosis$3.84M-34.6%28.2%
- Sports Medicine/Other$537K+20.1%4.0%
Forward guidance
OrthoPediatrics maintains suspension of its revenue growth and set consignment guidance for the full year 2020 due to the rapidly evolving environment and continued uncertainties surrounding the duration and impact of COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro